XVIVO PERFUSION AB (XVIPF:OTCMKTS)
$29.39 6.5792 (28.8425%)
Analysed XVIVO PERFUSION AB (XVIPF:OTCMKTS) News Sources
Annual Report 2025
01-04-2026
yahoo.com
The 12-Month Follow-up Results from XVIVO's European Multicenter Heart Trial is Now Published in the European Heart Journal
16-04-2026
yahoo.com
Conference Call on Interim Report January-March 2026
17-04-2026
yahoo.com
Late-Breaking Data from PRESERVE Trial Evaluates XVIVO’s HOPE Preservation Approach in Heart Transplantation
22-04-2026
yahoo.com
Preliminary One-Year Follow-up Data From the US Preserve Trial for XVIVO's Heart Technology Presented at ISHLT in Toronto
22-04-2026
yahoo.com
XVIVO Presents Encouraging Results From First Clinical Trial Using Hypothermic Oxygenated Perfusion (HOPE) In Direct Procurement DCD Heart Transplantation
22-04-2026
yahoo.com
Interim Report January - March 2026
24-04-2026
yahoo.com
Xvivo Perfusion AB (XVIPF) Q1 2026 Earnings Call Highlights: Strong Organic Growth and Positive ...
25-04-2026
yahoo.com
Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
27-04-2026
yahoo.com
Regulatory Derogation and Reimbursement in France Enable Life-Saving Use of XVIVO's Heart Technology
18-05-2026
yahoo.com
What is the current price of XVIVO PERFUSION AB (XVIPF:OTCMKTS)?
The current price of XVIVO PERFUSION AB (XVIPF:OTCMKTS) is $29.39.
XVIVO PERFUSION AB (XVIPF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of XVIVO PERFUSION AB (XVIPF:OTCMKTS) since the previous trading day is $6.5792.
XVIVO PERFUSION AB (XVIPF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of XVIVO PERFUSION AB (XVIPF:OTCMKTS) since the previous trading day is 28.8425%.
What is the most recent average sentiment score for XVIVO PERFUSION AB (XVIPF:OTCMKTS)?
The most recent average sentiment score for XVIVO PERFUSION AB (XVIPF:OTCMKTS) is 70 out of 100.
What is the most recent average sentiment for XVIVO PERFUSION AB (XVIPF:OTCMKTS)?
The most recent sentiment for XVIVO PERFUSION AB (XVIPF:OTCMKTS) is .
SEC-8K** Filing Available For XVIVO PERFUSION AB (XVIPF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.